Who We Are
INSIAS (In Silico Assessments) is committed to support pharmaceutical and biotech, as well as medical device companies in the qualification of their product related impurities while avoiding animal testing, whenever feasible.
When no adequate experimental mutagenicity and/or carcinogenicity results are available, a structure-based computational toxicology or (Q)SAR analysis may be used to predict the mutagenic potential of an impurity. (Q)SAR models are also available for other endpoints such as, but not limited to, irritation and sensitization.
Services
High quality reviews of in silico toxicity testing on small molecules
QSAR
basic review / detailed report
submit your chemical structure (mol file, smiles, jpeg, ...) and you'll receive a detailed report based on rule based and/or statistical models for prediction of the activities of new chemical entities or impurities you are facing.
Commercial (Q)SAR models we provide are: MultiCASE, LEADSCOPE and DEREK Nexus
QSAR
expert review, signed by certified Toxologist
In addition to the basic review, a full expert review and interpretation of the toxicity prediction will be performed and signed by a certified toxologist.
What if positive predictions need to be overruled?
In silico predictions can be overruled by in vitro or in vivo testing. Insias has access to a network of highly experienced CRO's who can perform AMES, LLNA and repeat dose toxicity studies.
In absence of the chemical entity, we can support you with our prequalified world class synthesis labs.